头颈部鳞癌术后放化疗后空间与剂量学复发模式分析
该研究回顾性分析203例头颈部鳞癌患者术后放化疗后的复发模式,中位随访39.7个月,HPV阴性患者3年局部、区域和远处控制率分别为84%、87%和87%。40例可分析复发中47.5%为高剂量区复发,择区照射野内孤立淋巴结复发率仅3%,支持术后放疗体积降级的可行性。
要点
- 术后放化疗后复发以高剂量区为主(47.5%),提示生物学抵抗是治疗失败的关键驱动因素。
- 择区照射野内孤立淋巴结失败率为3%(6/203),支持术后放疗体积降级的可行性。
- 体积降级可能不仅适用于HPV相关口咽癌,在准确淋巴结分期前提下也可考虑用于HPV阴性肿瘤。
核心结论
- 高剂量区复发占主导提示生物学肿瘤抵抗是治疗失败的关键驱动因素,需完善术后风险分层并将肿瘤生物学纳入剂量递增决策。
- 择区照射颈部的孤立淋巴结复发率低,支持术后放疗体积降级的可行性,可能适用于HPV相关口咽癌及HPV阴性肿瘤(需准确淋巴结分期)。
研究设计与样本
- 回顾性分析2017至2021年接受根治性术后放化疗的203例HNSCC患者(75% HPV阴性,25% HPV阳性)。
- 复发影像与计划CT配准,复发肿瘤体积与靶区剂量进行剂量学比较,并采用基于质心的空间分析方法。
- 复发分为五型:A(中央高剂量)、B(周边高剂量)、C(中央中/低剂量)、D(周边中/低剂量)、E(野外剂量)。
主要发现
- 中位随访39.7个月,HPV阴性HNSCC的3年局部、区域和远处控制率分别为84%、87%和87%。
- 56例复发中,局部17例、区域13例、局部区域3例、局部/区域伴远处失败9例、仅远处失败14例。
- 40例可分析复发中,47.5%为A/B型,5%为C/D中剂量型,20%为E型(其中一半为第二原发癌)。
- 择区靶区内C/D低剂量复发占27.5%(11/40),其中真淋巴结失败占15%(6/40),总择区颈部失败率为3%(6/203)。
临床怎么用
- 术后风险分层需结合肿瘤生物学因素,高剂量区复发为主提示单纯剂量递增可能不足以克服生物学抵抗。
- 在准确淋巴结分期基础上,术后放疗择区颈部体积降级可能可行,且可能不限于HPV相关口咽癌。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Advancements in nodal staging for head and neck squamous cell carcinoma (HNSCC) have prompted radiotherapy de-escalation trials to reduce irradiation of electively treated neck regions, with the goal of improving treatment tolerability. While volumetric de-escalation has shown promise in definitive radiotherapy of HNSCC, limited data exist regarding its safety in the postoperative treatment setting. This study aimed to assess dose-level-specific locoregional recurrence patterns following standard postoperative (chemo)radiotherapy in a mixed HNSCC cohort to inform risk-adaptive radiotherapy strategies. MATERIALS AND METHODS: We retrospectively reviewed 203 HNSCC patients (75% HPV-negative, 25% HPV-positive) treated with curative intent postoperative (chemo)radiotherapy from 2017 to 2021. Recurrence imaging was co-registered with planning CT, and recurrent tumor volumes were dosimetrically compared to the target volume dose and spatially analyzed using a center-of-mass-based approach. We classified five recurrence types: A (central high-dose), B (peripheral high-dose), C (central intermediate- or low-dose), D (peripheral intermediate- or low-dose), and E (extraneous dose). RESULTS: With a median follow-up of 39.7 months, the three-year local, regional, and distant control of HPV-negative HNSCC were 84%, 87%, and 87%, respectively. Of 56 recurrences, 17 were local, 13 regional, 3 locoregional, 9 combined local/regional with concomitant distant failure, and 14 distant only. Of 40 analyzed recurrences, we identified 47.5% as type A/B, 5% as type C/D intermediate-dose, and 20% as type E, half of which were secondary cancers. Among the 27.5% (11/40) type C/D low-dose recurrences in the elective target volume, 15% (6/40) were true nodal failures, resulting in an overall elective neck failure rate of 3% (6/203). CONCLUSION: The predominance of high-dose recurrences suggests that biological tumor resistance is a key driver of treatment failure, highlighting the necessity to refine postoperative risk stratification and integrate tumor biology into dose escalation decisions. The low incidence of isolated nodal recurrences in electively treated neck regions supports the feasibility of volumetric de-escalation of postoperative radiotherapy. This approach might not only be feasible for HPV-associated oropharyngeal cancers but also for HPV-negative tumors, provided that accurate nodal staging has been conducted.
引用
- Schröter P, Lau HH, Stritzke F, et al. Combined Spatial and Dosimetric Recurrence Pattern Analysis in Head and Neck Squamous Cell Carcinoma Following Postoperative (Chemo)radiotherapy. Radiat Oncol. 2025. PMID: 40269897. doi:10.1186/s13014-025-02641-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。